Evolution of motor fluctuations in Parkinson's disease: A longitudinal study over 6 years

Movement Disorders

Volumn 14, Issue 4, 1999, Pages 605-611

  Reardon, Katrina A ^b   Shiff, Mark ^b   Kempster, Peter A ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b NONE

Author keywords

Dyskinesia; L dopa; Motor fluctuation; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; CELL LOSS; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROTRANSMISSION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0033452735     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199907)14:4<605::AID-MDS1009>3.0.CO;2-H     Document Type: Article

References (15)

1. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
2. Nutt JG, Woodward WK, Carter JH, Gancher ST. Effect of long term therapy on the pharmacodynamics of levodopa. Arch Neurol 1992;49:1123-1130.
3. Hughes AJ, Daniel SE, Kifford L, Lees AJ. Accuracy of clinical diagnosis in idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
4. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-723.
5. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth International Medical Reviews, Neurology 2, 1982:96-112.
6. Hughes AJ, Frankel JP, Kempster PA, Stern GM, Lees AJ. Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. J Neurol Neurosurg Psychiatry 1994;57:430-434.
7. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
8. Canter CJ, de la Torre R, Mier A. A method of evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 1961; 133:143-147.
9. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
10. Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997;20:523-530.
11. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa in Parkinson's disease. Q J Med 1980;195:283-293.
12. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280: 337-345.
13. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
14. Boyce S, Clarke CE, Luquin R, et al. Induction of chorea and dystonia in parkinsonian primates. Mov Disord 1990;5:3-7.
15. Bonnet A-M, Loria Y, Saint-Hillaire M-H, Lhermitte F, Agid Y. Does long term aggravation of Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1987; 37:1539-1542.